Follow the Caris Life Sciences, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.4bn. The latest transaction was disclosed on 14 August 2026 (Attribution). Among the most active insiders: HALBERT JON. The full history is openly available.
43
Insider Decl.
n/a
Thresholds
€946,803
3 ops.
Buy Volume
€17m
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Caris Life Sciences, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
36Σ signal
Buys €946,803€17m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,153 of 28,799 companies
16.7
score / 100
Value
24
Quality
10
FCF yld-3.8%
Earn yld-4.8%
EV/EBITDA·
ROE-40%
Gross mgn·
Net mgn-16%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
2,500 shares@ US$18.60100.0% of flowCommon StockSEC:0001239594-26-000003:0
25 of 43 declarations
About Caris Life Sciences, Inc.
Caris Life Sciences, Inc. is a precision medicine company that provides diagnostic solutions and genomic testing to help personalize patient treatments. It is listed on NASDAQ under the ticker XNAS.